Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACME LaboratoriesDHA:ACMELAB -0.95%85 3-Year ROIIC % is 12.02 as of Jun. 2024, which is 34% above its 10-year median of 9.00. GuruFocus rates DHA:ACMELAB with a GF Score™ of 85/100 and a GF Value™ of BDT126.14 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 947 Drug Manufacturers companies, ACME Laboratories ranks better than 62.51% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
ACME Laboratories's 3-Year ROIIC % for the quarter that ended in Jun. 2024 was 12.02%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for ACME Laboratories's 3-Year ROIIC % or its related term are showing as below:
DHA:ACMELAB's 3-Year ROIIC % is ranked better than 62.51% of 947
companies
in the Drug Manufacturers industry
Industry Median: 3.7
vs DHA:ACMELAB: 12.02
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ACME Laboratories 3-Year ROIIC % Related Terms
ACME Laboratories 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
ACME Laboratories (DHA:ACMELAB) has a 3-Year ROIIC % of 12.02 as of Jun. 2024. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ACME Laboratories and its competitors. This is 34% above median its historical median of 9.00. Over the past decade, ACME Laboratories' 3-Year ROIIC % has ranged from 4.71 to 16.24. According to the industry distribution chart, ACME Laboratories ranks #355 out of 947 companies in the Drug Manufacturers industry, placing it in the top 37.5%.
Is ACME Laboratories' 3-Year ROIIC % too high?
ACME Laboratories' current 3-Year ROIIC % of 12.02 is 34% above median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 4.71 to a high of 16.24. The Drug Manufacturers industry median 3-Year ROIIC % is 3.70. ACME Laboratories' value of 12.02 is 224.9% above this industry median. Based on the distribution chart, ACME Laboratories ranks #355 out of 947 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ACME Laboratories has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #355 out of 947 companies for 3-Year ROIIC %. This puts ACME Laboratories in the upper half of its industry. The industry median 3-Year ROIIC % is 3.70. ACME Laboratories' value of 12.02 is 224.9% above this benchmark. Historically, ACME Laboratories' own 3-Year ROIIC % has ranged from 4.71 to 16.24 over the past decade. While the company's 10-year median is 9.00 vs. the industry median of 3.70, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.70, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current 3-Year ROIIC % of 12.02 is 224.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current 3-Year ROIIC % is 12.02, which is 34% above median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT126.14, compared to a current price of BDT83.50 — trading 33.8% below its estimated fair value. The current 3-Year ROIIC % is 12.02, which is 34% above median its 10-year median of 9.00 and 224.9% above the Drug Manufacturers industry median of 3.70. ACME Laboratories' overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current 3-Year ROIIC % is 12.02 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT83.50 is trading 33.8% below its estimated GF Value™ of BDT126.14.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
3-Year ROIIC %: 12.02 (34% above median its 10-year median of 9.00)
GF Value™: BDT126.14 vs. price of BDT83.50 (33.8% below fair value)
Industry Position: 224.9% above the Drug Manufacturers median (#355 of 947)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
85GF Score
Get the complete analysis for DHA:ACMELAB
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
